Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer

dc.contributor.authorBarakat, Andrew
dc.contributor.authorYacoub, Basel
dc.contributor.authorEl Homsi, Maria
dc.contributor.authorSaad Aldine, Amro
dc.contributor.authorEl Hajj, Albert Elias
dc.contributor.authorHaidar, Mohamad B.
dc.contributor.departmentDiagnostic Radiology
dc.contributor.departmentSurgery
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:41:09Z
dc.date.available2025-01-24T11:41:09Z
dc.date.issued2020
dc.description.abstractGa-68 Prostate-Specific Membrane Antigen PET/CT is a new tool for the assessment of prostate cancer. Standard imaging time is 60 minutes post injection of radiotracer. At 60 minutes, there is physiologic accumulation of radiotracer in the urinary bladder which may cause some lesions in its vicinity to be obscured. Our aim is to determine if early imaging at 3 minutes in addition to standard imaging at 60 minutes can improve the detection of PSMA-avid lesions. A retrospective review of 167 consecutive patients was conducted. Overall, 115 patients (68.9%) were ruled to have prostate cancer based on imaging as seen on early or standard PET/CT images. In 106/115 (64%), the lesions were detected on both early and standard imaging; in 8/115 (6.9%), the lesions were only detected on early imaging; in 1/115 (0.6%) the lesion was detected only on standard imaging. The addition of early imaging significantly improved the overall detection rate of PSMA-avid lesions (p = 0.039). The ratio of patients with lesions detected on early imaging but not on standard imaging in restaging group was 7/88 and was higher than that in staging group 1/79 (p = 0.043). We recommend early imaging in addition to the standard imaging in Ga-68 PSMA PET/CT, particularly in patients presenting for restaging of prostate cancer. © 2020, The Author(s).
dc.identifier.doihttps://doi.org/10.1038/s41598-020-59296-6
dc.identifier.eid2-s2.0-85079657609
dc.identifier.pmid32066750
dc.identifier.urihttp://hdl.handle.net/10938/29684
dc.language.isoen
dc.publisherNature Research
dc.relation.ispartofScientific Reports
dc.sourceScopus
dc.subjectAged
dc.subjectEarly detection of cancer
dc.subjectHumans
dc.subjectImage interpretation, computer-assisted
dc.subjectMale
dc.subjectMembrane glycoproteins
dc.subjectMiddle aged
dc.subjectNeoplasm recurrence, local
dc.subjectNeoplasm staging
dc.subjectOrganometallic compounds
dc.subjectPositron emission tomography computed tomography
dc.subjectProstate
dc.subjectProstatic neoplasms
dc.subjectRadiopharmaceuticals
dc.subjectRetrospective studies
dc.subjectUrinary bladder
dc.subject68ga-psma
dc.subjectMembrane protein
dc.subjectOrganometallic compound
dc.subjectRadiopharmaceutical agent
dc.subjectBladder
dc.subjectCancer staging
dc.subjectComputer assisted diagnosis
dc.subjectDiagnostic imaging
dc.subjectEarly cancer diagnosis
dc.subjectHuman
dc.subjectMetabolism
dc.subjectPathology
dc.subjectPositron emission tomography-computed tomography
dc.subjectProcedures
dc.subjectProstate tumor
dc.subjectRetrospective study
dc.subjectTumor recurrence
dc.titleRole of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-6407.pdf
Size:
867.45 KB
Format:
Adobe Portable Document Format